You just read:

Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy

News provided by

Trovagene, Inc.

Apr 02, 2019, 08:00 ET